drugset / Trial / NCT02336542

Summary

96 TB subjects and 96 non-TB subjects with lung disease who all meet the standard are divided into different groups through a randomized, blind methods.Every subject inject intradermally ESAT6-CFP10 and TB-PPD in different arms of the same person.Specific γ- IFN(gamma interferon) detection is needed before the injection.Evaluate the sensitivity (positive coincidence rate) ,the specificity (negative coincidence rate) and the coincidence rate of ESAT6-CFP10 in the tuberculosis patients and non-tuberculosis patients with lung diseases, and determine the optimal dose of ESAT6-CFP10 for clinical auxiliary diagnosis of tuberculosis.

Timeline

Start
2014-11
Primary completion
2015-07
Completion
2015-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ESAT6-CFP10 Protein / enzyme biologic 5 ug/ml Intrathecal
Subject ESAT6-CFP10 Protein / enzyme biologic 10 ug/ml Intrathecal
Subject TB-PPD Diagnostic / imaging agent Intrathecal

Indications